Tony Mattair

Sales Training | Leadership Development | Sales Leadership

Role: Executive Director, Sales Training & Development at Humacyte
Location: Easton, PA, US
LinkedIn followers: 500 followers

About Tony Mattair

Experienced Sales Leader with a demonstrated history working in the biotechnology and medical technology industries. Skilled in Sales Training, Management, Medical Devices, Sales, Pharmaceutical Sales, and Product Launch. Strong healthcare services professional with a Master of Science (M.S.) Organizational Development & Leadership from Saint Joseph\'s University.

Experience

Executive Director, Sales Training & Development
Humacyte
May 2024 — Present

Education

University of Delaware
BA, Political Science
1994 — 1996
Saint Joseph's University
Master of Science (M.S.), Organizational Development & Leadership
2016 — 2018

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@humacyte.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Humacyte

Biotechnology Research · 164 employees · Founded 2004 · Durham, North Carolina, United States

Humacyte, Inc. (Nasdaq: HUMA) is proud to announce that in Dec 2024, FDA granted full approval for our Acellular Tissue Engineered Vessel (ATEV), a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries.See the Prescribing Information, including Boxed Warning: https://bit.ly/4dl5tuL This is the first approval in our bioengineered ATEV Platform where we are continuing to investigate use of our lab-grown tissues and organs to improve the lives of patients and transform the practice of medicine. We develop and manufacture acellular tissues that are meant to be universally implantable and remodel with the patient's own cells over time. The goal is to grow spare parts for people. Humacyte’s ATEV is in clinical trials for arteriovenous access for hemodialysis, and peripheral arterial disease. Investigational preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s ATEV for performing hemodialysis in AV Access was the first indication to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the ATEV technology received priority designation for the treatment of extremity arterial repair by the U.S. Secretary of Defense prior to its FDA approval in Dec 2024 for that purpose. For more information, visit https://Humacyte.com.

humacyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Tony Mattair

Experience

Executive Director, Sales Training & Development

Education

University of Delaware

Saint Joseph's University

Find verified contacts for anyone on LinkedIn